$MRK [15s. delayed]: Issued Press Release on June 05, 06:50:00: FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) https://t.co/nQE6d1Jibo